Replies to post #3627 on Synaptogenix Inc (SNPX)

[runncoach]

You'll see multiple analysts coverage of this stock IF results are statistically significant in the next week with price targets in the $75 to $100+ range based on market cap in the 500+ million minimum range followed by national press coverage. If Aegis if first in the game, i hope they do get a piece of the action when big pharma comes knocking this spring. We just have to see if we have the goods and we should know around this time next week. JMHO

[xIdXd]

Sure looks like a terrible attempt at pumping the stock then, considering its down more than 2% since their first report, not to mention that their report clearly states they don't own shares of the company.

I'm honestly kind of impressed of how low the volume has been so far, not to mention how stable the price has been ($18-20) for the last 2 months.

First I thought I was crazy for not seeing something that everyone else could apparently see, but the more I do my research, the more I'm convinced that people simply don't have a clue what NTRP is about.

Either that, or the big boys are simply waiting with their fingers over the button until results are released.

[SF Wolf]

Your logic is faulty. The part you are leaving out is that of the
150,000,000 shares authorized none have been sold or issued. It appears that NTRP will raise money after the Ph2b results are released not before.

If the Aegis report was a true pump job Neurotrope would already be in the market with an offering before results, that is just not the case.

The company has no debt, approximately $20 million in the bank, $50 plus million in outstanding warrants and options when exercised, and now, once results are out, the opportunity to raise additional funds at a much higher market cap. That will give them leverage when they negotiate with a Big Pharma suitor or they can pursue there own Ph3 and Ph2b open label follow-on studies .

Neurotrope has made all of the right moves.